Sign In
Buy ATI
$197.80
-2.04 (-1.02%)
At Close: Jul 24, 2026
ATI (ATI) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 30'th Mar 2026
ATI (ATI) possesses solid growth attributes, which could help it handily outperform the market.
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEW
Is ATI (ATI) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Thursday, 26'th Mar 2026
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
ATI vs. CRS: Which Specialty Metals Stock Should You Invest in Now?
11:15am, Wednesday, 25'th Mar 2026
ATI Inc. ATI and Carpenter Technology Corporation CRS are two prominent players in the specialty metals space, with a focus on high-performance alloys for aerospace, defense and industrial application
Are Aerospace Stocks Lagging ATI INC (ATI) This Year?
10:42am, Wednesday, 25'th Mar 2026
Here is how ATI (ATI) and RTX (RTX) have performed compared to their sector so far this year.
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat
ATI (ATI) Falls More Steeply Than Broader Market: What Investors Need to Know
07:15pm, Thursday, 19'th Mar 2026
The latest trading day saw ATI (ATI) settling at $147.54, representing a -1.4% change from its previous close.
Can ATI Sustain Its Robust Free Cash Flow Momentum in 2026?
01:46pm, Wednesday, 18'th Mar 2026
ATI targets up to $490M free cash flow in 2026 after strong 2025 gains, backed by demand strength, pricing power, and reduced seasonality.
Why ATI (ATI) is a Top Growth Stock for the Long-Term
10:46am, Wednesday, 18'th Mar 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
06:55am, Wednesday, 18'th Mar 2026
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused
ISCG vs. VBK: Which ETF Offers Lower Fees, More Liquidity, and Greater Returns?
11:35am, Tuesday, 17'th Mar 2026
Portfolio breadth, sector mix, and subtle cost differences set these small-cap growth ETFs apart for investors weighing their next move.
ATI Inc. $ATI Shares Bought by Bank of Nova Scotia
03:40am, Tuesday, 17'th Mar 2026
Bank of Nova Scotia grew its position in ATI Inc. (NYSE: ATI) by 11.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 265,053 shares of the b
3 Reasons Growth Investors Will Love ATI (ATI)
01:46pm, Friday, 13'th Mar 2026
ATI (ATI) could produce exceptional returns because of its solid growth attributes.
ATI: Aerospace Supercycle Meets Material Scarcity
10:01am, Friday, 13'th Mar 2026
ATI Inc. is positioned at the intersection of structural demand growth and constrained supply, driving pricing power and margin expansion. ATI's high-performance alloys are critical for aerospace, def
IJT Plays Small-Cap Growth With Guardrails, ISCG Goes All In
04:09pm, Thursday, 12'th Mar 2026
Explore how these two small-cap growth ETFs differ in cost, diversification, and risk to help refine your investment strategy.
